WOODCLIFF LAKE, NJ
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE DESMOID TUMOR RESEARCH FOUNDATION, founded in 2005, is a small nonprofit in the Medical Research sector that reported $793K in total revenue in fiscal year 2024. Revenue surged 138% from the prior year, signaling strong growth momentum. The organization ran a surplus of $202K, a strong 25% operating margin.
THE DESMOID TUMOR RESEARCH FOUNDATION (DTRF) EMPOWERS AND UNITES EVERYONE COMMITTED TO FINDING ANSWERS FOR THE DESMOID TUMOR COMMUNITY.
WE AGGRESSIVELY FUND DESMOID TUMOR RESEARCH, ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES, DRIVE COLLABORATIONS AMONG CLINICIANS AND RESEARCHERS WORLDWIDE, AND SUPPORT PATIENTS AND DOCTORS...
WE AGGRESSIVELY FUND DESMOID TUMOR RESEARCH, ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES, DRIVE COLLABORATIONS AMONG CLINICIANS AND RESEARCHERS WORLDWIDE, AND SUPPORT PATIENTS AND DOCTORS THROUGH EDUCATION. OUR GOAL IS TO FIND A CURE FOR EACH AND EVERY PATIENT DIAGNOSED WITH THIS RARE DISEASE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $792,998 | $333,727 | +1.4% |
| Expenses | $590,934 | $707,649 | -0.2% |
| Net Income | $202,064 | $-373,922 | -1.5% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| BARARA ANN SELLINGER | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| STEVE WHITING | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| NICOLE DEICHERT | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MARIA CROCITTO | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JERROLD MARCH | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| RACHEL SITTA | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MARLENE PORTNOY | CHAIR | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| JEANNE WHITING | PRESIDENT/FORMER EXECUTIVE DIRECT | 20.00 |
Officer
Director
|
$6,875 | $0 | $6,875 |
| TOM ALLEN | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DJ CONNER | TREASURER | 4.00 |
Director
|
$0 | $0 | $0 |
| YATING WONG | DIRECTOR | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| LYNNE HERNANDEZ | EXECUTIVE DIRECTOR | 40.00 |
Officer
|
$95,000 | $0 | $95,000 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $792,998 | $590,934 | $1,277,054 | $202,064 |
| 2023 | $333,727 | $707,649 | $1,034,489 | $-373,922 |
| 2022 | $993,749 | $712,927 | $1,439,427 | $280,822 |
| 2021 | $710,377 | $705,016 | $1,128,637 | $5,361 |
| 2020 | $548,284 | $471,645 | $1,161,128 | $76,639 |
| 2019 | $718,276 | $589,894 | $1,054,967 | $128,382 |
| 2018 | $714,396 | $616,174 | $921,341 | $98,222 |
| 2017 | $558,443 | $683,155 | $824,690 | $-124,712 |
Compare THE DESMOID TUMOR RESEARCH FOUNDATION with other nonprofits in New Jersey and across the country.